Ortho Pharmaceutical Corporation

Johnson Matthey Inc.

Michael Bornstein

Rosemary Rozman

Kevin Francis Long

N Adeyinka Williams

Robert L Suddith

Scott K Larsen

Michelle L Tomsho

Diane C Corbo

Howard F Solomon

Mary Jean Link

George Kaon Wong

Hsiao Yung Guh

A lyophilized imaging agent formulation and methods for making same are disclosed, such formulations comprise a targeting molecule such as antibody or chemotactic peptide, a linker such as diethylenetriaminepentaacetic acid (DTPA) or succinimidyl 6-hydrazinium nicotinate hydrochloride (SHNH), drying protectant such as mannitol, maltose or tricine, and excipient such as polysorbate 80, in citrate buffer. The formulations of the invention are lyophilized and may be stored stably for extended periods of time. Following reconstitution with diluent, the formulations are administered to a subject for scintigraphic imaging or therapeutic use. Also contemplated is a kit comprising a two-vial system wherein a first vial comprises a lyophilized formulation of imaging agent in the form of a lyophilized cake, and a second vial comprises a pharmaceutically acceptable carrier or diluent.

Lyophilized imaging agent formulation comprising a chemotactic peptide

An improved solid pharmaceutical composition comprising a lyophilized liposomal KL4 pulmonary surfactant composition comprising:

Lyophilized pulmonary surfactant peptide compositions

Shelf stable formulations of 2-CdA in water are disclosed which contain benzyl alcohol and, optionally, propylene glycol.

Soluble 2-chloro-2'-deoxyadenosine formulations

Shelf stable formulations of 2-CdA in water are disclosed which contain benzyl alcohol, m-cresol, a buffer and sodium chloride or a solubilizing agent such as propylene glycol or polyethylene glycol.

Stable 2-chloro-2'-deoxyadenosine formulations

Growing community of inventors

Westfield, NJ, United States of America

Michael Bornstein